BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug

 
• By Neena Brizmohun
  
NICE said BioMarin's asking price for its Batten disease treatment was too high for routine use. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Market Access